Please login to the form below

Not currently logged in
Email:
Password:

Novartis India leader responds to Glivec patent rejection

The head of Novartisí Indian operations has responded to the Glivec cancer drug patent ruling.

The head of Novartisí Indian operations has responded to the Glivec cancer drug patent ruling.

"India is not open for business," said Rajit Shahani in an interview with the Wall Street Journal website, Livemint.com.

In early August 2007, the court issued its decision to uphold the Indian Patents Act and dismissed Novartis' writ petition challenging constitutionality of Section 3(d), regarding incremental innovation.

The Swiss company filed an appeal after its patent application for Glivec was rejected. The drug has been granted patent in approximately 40 countries, including China; but was denied in India in 2006. Novartis challenged the section that it claims does not permit patent to medicines with safety advantages.

"Indian pharma companies and multinational drug makers push for changes in opposite directions on matters such as price control, data protection and definition of patentability," accused Shahani.

He concluded: "Novartis is likely not to appeal the decision. Our actions have advanced this essential debate in India, now itís up to the relevant political leaders and groups to work together to strengthen Indiaís patent law."

24th August 2007

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Market Access Transformation

Market Access Transformation (MAT), founded by industry veterans Baiju Aurora and Paul Howard, specializes in developing cutting edge technologies that...

Latest intelligence

How can we strike the right balance between familiarity and innovation when it comes to data presentation?
Following our webinar in March, Getting MedComms right: navigating the age of the amateur expert, we’re taking the time to respond to questions we were unable to answer during the...
Deep 6 AI: the smart software breathing new life into clinical trials
Fishawack Health interviews Wout Brusselaers, the Deep 6 AI CEO using artificial intelligence to solve one of the greatest barriers stagnating healthcare innovation—clinical trial recruitment and retention....
COVID-proof: How Teams are Creating Launch Intensity thru Adversity
Now that the game has changed, how are marketers shifting their launch behaviour? We've identified 5 common observations from effective teams....